2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.

Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed. New data on imaging and clinical diagnosis have become available since the first EULAR recommendations for the diagnosis of gout in 2006. This prompted a systematic review and update of the 2006 recommendations.

2016 updated EULAR evidence-based recommendations for the management of gout.

Background: New drugs and new evidence concerning the use of established treatments have become available since the publication of the first European League Against Rheumatism (EULAR) recommendations for the management of gout, in 2006. This situation has prompted a systematic review and update of the 2006 recommendations.

Methods: The EULAR task force consisted of 15 rheumatologists, 1 radiologist, 2 general practitioners, 1 research fellow, 2 patients and 3 experts in epidemiology/methodology from 12 European countries.

[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up].

Aim: To estimate the time course of changes in the clinical manifestations of gout and their risk factors during a long-term follow-up.

Subjects And Methods: A total of 160 male patients with gout were examined and followed up for a mean of 6.9 ± 2.

Comparison of three imaging techniques in diagnosis of chondrocalcinosis of the knees in calcium pyrophosphate deposition disease.

Objective: To study the role of different imaging modalities, ultrasonography, conventional radiography (CR) and CT, in visualization of chondrocalcinosis of the knees in patients with CPDD.

Methods: Twenty-five patients (14 males and 11 females) with CPDD were enrolled in the study. Diagnosis was made according to D.

[Main factors of gender dimorphism of gout (estrogens and diuretics vs alcohol and genetics)].

The article analyses factors underling gender dimorphism of gout, gender epidemiological differences. Discussion covers the role of estrogens and menopause, alcohol, diuretics, gender-associated genetic characteristics in gout genesis.

EULAR recommendations for calcium pyrophosphate deposition. Part II: management.

Objectives: To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD).

Methods: A multidisciplinary guideline development group of 15 experts, representing 10 European countries, generated key propositions for management of CPPD using a Delphi consensus approach. For each recommendation research evidence was searched systematically.

European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.

Objectives: To agree terminology and to develop recommendations for the diagnosis of calcium pyrophosphate deposition (CPPD).

Methods: The European League Against Rheumatism (EULAR) CPPD Task Force, comprising 15 experts from 10 countries, agreed the terms and recommendations for diagnosis of CPPD using a Delphi consensus approach. Evidence was systematically reviewed and presented in terms of sensitivity, specificity and positive likelihood ratio (LR) to support diagnosis; ORs were used for association.

[Carbohydrate metabolic disorders in gout: incidence and clinical features].

Aim: To study the clinical features of gout concurrent with carbohydrate metabolic disturbances.

Subjects And Methods: One hundred and ninety-five patients with gout were examined. Their mean age was 54.

International position paper on febuxostat.

This position paper aims to clarify the presumed place of febuxostat in the management of gout patients. Since this novel xanthine oxidase inhibitor is now available, an international group of gout experts decided to formulate an international consensus statement. This statement presents the place for this new xanthine oxidase inhibitor in the treatment of gout which may contribute to optimize treatment of gout patients in Europe and worldwide.

[Chronic gout: causes, clinical manifestations, treatment].

Why chronic gout, that is mostly a well diagnosed and controlled disease if it is timely and systematically treated with allopurinol, becomes a topical public health problem following 50 years after the introduction of pathogenetic therapy with xantine oxidase inhibitors is under consideration. The principles of rational therapy for chronic gouty arthritis are outlined.

[Relationship between the intima-media complex thickness, the risk factors of cardiovascular diseases, and the level of C-reactive protein in gouty patients].

Aim: To estimate a relationship between the intima-media thickness (TIM), cardiovascular risk (CVR) factors, and the level of C-reactive protein (CRP) in gouty patients.

Subjects And Methods: Eighty-nine patients at an interattack interval were examined. The patients' mean age was 46.

[Effect of metformin on the clinical course of gout and insulin resistance].

Unlabelled: The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR). The study included 30 patients (28 men and 2 women) of mean age 51 yr and duration of he disease 4-11 yr. IR was diagnosed based on the HOMA index.

[Metabolic syndrome in gout].

The presence of metabolic syndrome (MS) is characteristic for many patients with gout. MS is closely associated with a generalized disorder called insulin resistance (IR) or impaired tissue responsiveness to the normal action in insulin. MS and IR define cardiovascular disease risks and are the main factors leading to severe disease associated with chronic arthritis and struck joints in gout patients.

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.

Objectives: To reach consensus with recommendations made by an OMERACT Special Interest Group (SIG).

Methods: Rheumatologists and industry representatives interested in gout rated and clarified, in three iterations, the importance of domains proposed by the OMERACT SIG for use in acute and chronic gout intervention studies. Consensus was defined as a value of less than 1 of the UCLA/RAND disagreement index.

[Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac].

Aim: To compare the time to presentation of the analgetic and anti-inflammatory effects of granulated and tablet nimesulide and sodium diclofenac since the start of therapy for gouty arthritis (GA).

Material And Methods: Ninety males with gout were randomized into 3 equal groups. The patients were included in the study by the following criteria: a documented diagnosis of gout (Wallace S.

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Objective: To develop evidence based recommendations for the diagnosis of gout.

Methods: The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert, representing 13 European countries. Ten key propositions regarding diagnosis were generated using a Delphi consensus approach.

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Objective: To develop evidence based recommendations for the management of gout.

Methods: The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert representing 13 European countries. Key propositions on management were generated using a Delphi consensus approach.

[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].

Aim: To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR).

Material And Methods: The trial included 26 patients with gout (criteria of the American collage of rheumatologists) and IR (index HOMA). The inclusion criteria were the following: absence of antigout therapy, normal hepatic and renal function, rejection of alcohol.

[Markers of vascular endothelium activation in gout].

Aim: To determine clinical significance of laboratory markers of vascular endothelium activation in gout.

Material And Methods: A total of 16 males aged 31-68 years with gout entered the study. The diagnosis satisfied Vallas' criteria, duration of the disease varied from 1.

[Severity of a female gout course].

Aim: Comparison of a gout course in males and females.

Material And Methods: The trial enrolled 34 patients (17 females and 17 males). The patients were matched by age and the disease duration.